



Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.com

CIN L85195MP1988PLC004446

Date: -6th February, 2017

To,
Listing Department,
BSE Limited.
Rotunda Building, P J Towers
Dalal Street, Fort,
Mumbai – 400 001

To,
Listing Department,
National Stock Exchange of India Limited.
'Exchange Plaza', C-1, Block G,
Bandra - Kurla Complex,
Bandra (E), Mumbai – 400 051

Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Reference :- Scrip Code: 532878 ; Scrip Code: ALPA ; ISIN: INE385I01010

Dear Sir/ Madam,

This is to inform you that pursuant to provisions of Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the meeting of the Board of Directors of the Company was held today that is on **Monday, 6th February, 2017** at registered office of the Company situated at 33/2, A.B Road, Pigdamber Rao, Indore, Madhya Pradesh has approved the following matter:

1. Approval of Standalone Un-Audited Financial Results of the Company for quarter ended 31st December , 2016 along with Limited Review Report.

The Board meeting commenced at 04.00 P.M and concluded at 5.30 P.M.

Please find enclosed herewith the copy of approved Standalone Un-Audited Financial Results of the Company for quarter ended 31st December , 2016 along with Limited Review Report.


Kindly take same for your records and oblige.

Thanking you,

Yours Faithfully

For Alpa Laboratories Limited

Megha Neema
Megha Neema
Company Secretary



Encl: a/a

ALPA LABORATORIES LIMITED
33/2 PIGDAMBER, A.B. ROAD, RAU INDORE (M.P.) 453446

(₹ In lac unless stated)

Statement of Standalone Un audited Financial Results for Quarter & Period ended 31st Dec. 2016

Particulars	Quarter Ended			Nine Month Ended		Year Ended
	Dec-16	Sep-16	Dec-15	For Nine Month Ending On 31.12.2016	For Nine Month Ending On 31.12.2015	Year Ended March 2016
	Unaudited					Audited
(a) Net sales/income from operations	1684.26	1204.25	1271.98	4388.30	3294.21	5063.25
(Net of Excise duty)						
(b) Other operating income	24.03	25.42	10.61	62.88	61.68	286.96
1. Total income from operations (net) (a+b)	1708.29	1229.67	1282.59	4451.18	3,355.89	5,350.20
(c) Cost of materials consumed	1065.91	713.21	777.18	2752.90	1811.41	3186.14
(d) Purchases of stock-in-trade	-	-	-	-	-	-
(e) Changes in inventories of fin. goods, stock-in-pro. & stock-in-trade	-62.70	-100.35	138.41	-229.30	-325.74	-398.32
(f) Employee benefits expense	218.82	190.63	167.96	594.58	511.16	717.45
(g) Depreciation and amortization expense	18.37	18.00	22.04	53.99	60.99	83.09
(h) Other expenses	302.62	215.78	341.26	755.51	791.74	1163.35
2. Total expenses (c+d+e+f+g+h)	1543.02	1037.27	1446.85	3927.68	2849.56	4751.71
3. Profit/ Loss(-) from operations before other income and finance cost and Exceptional items (1-2)	165.27	192.40	-164.26	523.50	506.33	598.49
4. Other income	186.23	98.94	154.19	419.50	407.70	609.22
5. Profit/ Loss(-) from ordinary activities before finance costs and Exceptional items (3+4)	351.50	291.33	-10.07	943.01	914.03	1207.72
6. Finance costs	36.20	55.41	32.60	144.43	79.31	144.62
7. Profit/ Loss(-) from ordinary activities after finance cost but before exceptional items (5-6)	315.30	235.92	-42.67	798.58	834.72	1063.10
8. Exceptional items	-	211.53	-	211.53	-	-
9. Net Profit/ Loss(-) from ordinary activities before tax (7+/-8)	315.30	24.39	-42.67	587.05	834.72	1063.10
10. Tax expense	-	-	-	-	-	289.14
11. Net Profit/ Loss(-) from ordinary activities after tax (9-10)	315.30	24.39	-42.67	587.05	834.72	773.96
12. Loss from extraordinary activities	-	-	-	-	-	-
13. Net Profit & Loss after tax and Extraordinary Items (11+/-12)	315.30	*24.39	-42.67	587.05	834.72	773.96
14. Share of Profit (Loss) of Associates	-	-	-	-	-	-
15. Minority Interest (For Consolidated Result Only)	NA	NA	NA	NA	NA	NA
16. Net Profit & loss After Minority Interest and Share of Profit/ Loss of associates (13+14+15)	315.30	24.39	-42.67	587.05	834.72	773.96
17. Paid-up equity share capital (Face Value `10 Each)	2104.06	2104.06	2104.06	2104.06	2104.06	2104.06
18. Reserves excluding Revaluation Reserves as per bal. sheet of prev. year	-	-	-	-	-	7325.91
19 Basic and Diluted Earnings per share before extraordinary items* (not annualized)	1.50	0.12	-0.20	2.79	3.97	3.68
20 Basic and Diluted Earnings per share after extraordinary items* (not annualized)	1.50	0.12	-0.20	2.79	3.97	3.68

Notes -

1. The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today.

2. The Company is operating in the single segment of Drugs & Chemicals.

3. The Provision for Tax may not have been made for the partial/unaudited periods.

4. The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.





LIMITED REVIEW REPORT

REVIEW REPORT TO ALPA LABORATORIES LIMITED

We have reviewed the accompanying statement of unaudited financial results of **M/s Alpa Laboratories Limited for the quarter ended 31st December, 2016**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on review Engagement (SRE) 2400 Engagement to Review Financial Statement issued by the Institute of Chartered Accountant of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as above nothing has come to our attention that cause us to believe that the accompanying statement of unaudited results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 including the manner in which in which is to be disclosed, or that it contains any material misstatement.

Place: Indore

Date: This 06th Day of February, 2017

For: CH. Padliya & Co.

Chartered Accountants

FRN No. 003151C

(S.C. Padliya)

M.No. 071666